
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
BiotechTV - News
00:00
Outro
Amy thanks Stefanie Fluckiger-Mangual and closes the interview with plans to follow Tolremo’s future data.
Play episode from 07:41
Transcript


